Stereotactic Radiotherapy for Polypoidal Choroidal Vasculopathy: A Pilot Study
| Autor: | Usha Chakravarthy, Ugo Introini, Giuseppe Casalino, E. Mark Shusterman, Giacinto Triolo, Denis O'Shaughnessy, Francesco Bandello, Jason S. Slakter |
|---|---|
| Přispěvatelé: | Introini, U, Casalino, G, Triolo, G, O'Shaughnessy, D, Shusterman, Em, Chakravarthy, U, Slakter, J, Bandello, Francesco |
| Rok vydání: | 2014 |
| Předmět: |
Indocyanine Green
Male Vascular Endothelial Growth Factor A medicine.medical_specialty Visual acuity genetic structures Indocyanine green angiography Population Visual Acuity Angiogenesis Inhibitors Pilot Projects Antibodies Monoclonal Humanized Radiosurgery Stereotactic radiotherapy Polyps Pro re nata Ranibizumab Ophthalmology medicine Humans Fluorescein Angiography Coloring Agents Adverse effect education Aged Aged 80 and over education.field_of_study business.industry General Medicine Diabetic retinopathy Middle Aged medicine.disease Combined Modality Therapy Choroidal Neovascularization eye diseases Sensory Systems Intravitreal Injections Female sense organs medicine.symptom business medicine.drug |
| Zdroj: | Ophthalmologica. 233:82-88 |
| ISSN: | 1423-0267 0030-3755 |
| DOI: | 10.1159/000368561 |
| Popis: | Purpose: To evaluate low-voltage X-ray stereotactic radiotherapy (SRT) delivered in conjunction with intravitreal ranibizumab for the treatment of active macular polypoidal choroidal vasculopathy (PCV). Methods: At baseline, all eyes received an intravitreal injection of ranibizumab, followed by 16-Gy X-ray SRT to the macula. Further ranibizumab injections were given pro re nata. The primary outcome measure was regression of the polyps assessed by indocyanine green angiography. Secondary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) changes on optical coherence tomography. Local or systemic adverse events were evaluated as well. Results: We examined 12 eyes of 12 patients with PCV. At month 12, an angiographic regression of the polyps was observed in 10 of the 12 eyes. The mean BCVA improved by 7.6 letters: from 65.08 ± 11.4 to 72.7 ± 14.75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean CFT decreased from 372.3 ± 79.6 to 215.9 ± 57.9 µm (p < 0.01). No local or systemic adverse events were reported. Conclusions: The preliminary data support the safety of low-voltage X-ray SRT for the treatment of macular PCV and show polyp closure, reduction in CFT and improvement in the mean BCVA. Additional research is warranted to confirm the efficacy and longer-term safety of this therapy in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|